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Abstract
Introduction: We previously found that mesenchymal stem cells (MSCs) injected intravenously could attenuate
peritoneal adhesion by secreting tumor necrosis alpha-stimulating gene (TSG)-6, while MSCs injected
intraperitoneally could not. However, the underlying mechanism remains unclear. This study was designed to
investigate the means by which MSCs exert their effects.
Methods: Rat bone marrow-derived MSCs/red fluorescent protein (RFP) were injected either intraperitoneally or
intravenously into Sprague-Dawley (SD) rats at different time points after peritoneal scraping. Peritoneal adhesions
were evaluated macroscopically at day 14 after scraping. The distribution of MSCs injected intraperitoneally or
intravenously was traced by two-photon fluorescence confocal imaging and immunofluorescence microscopy. The
co-localization of MSCs and macrophages in the lung and the spleen, and the expression of TSG-6 in MSCs
trapped in the lung or the spleen were evaluated by immunofluorescence microscopy. The concentration of TSG-6
in serum was evaluated by ELISA. After intravenous injection of TSG-6- small interfering (si) RNA-MSCs, the
expression of TSG-6 in MSCs and the concentration of TSG-6 in serum were reevaluated, and peritoneal adhesions
were evaluated macroscopically and histologically.
Results: MSCs injected intraperitoneally failed to reduce peritoneal adhesion, and MSCs injected intravenously
markedly improved peritoneal adhesion. Two-photon fluorescence confocal imaging showed that MSCs injected
intravenously accumulated mainly in the lung, where they remained for seven days, and immunofluorescence
microscopy showed few MSCs phagocytosed by macrophages. In contrast, large numbers of MSCs accumulated in the
spleen with obvious phagocytosis by macrophages even at 4 hours after intraperitoneal injection. Immunofluorescence
microscopy showed that MSCs that accumulated in the lung after intravenous injection could express TSG-6 within 12
hours, but TSG-6-siRNA-MSCs or MSCs accumulated in the spleen after intraperitoneal injection did not. ELISA showed
that the concentration of TSG-6 in serum was increased at 4 hours after intravenous injection of MSCs, while there was
no increase after injection of TSG-6-siRNA-MSCs or after intraperitoneal injection of MSCs. Moreover, intravenous
injection of TSG-6-siRNA-MSCs failed to attenuate peritoneal adhesion.
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Conclusions: Our findings suggest that intravenously injected MSCs accumulated in the lung and attenuated
peritoneal adhesion by secreting TSG-6, but intraperitoneally injected MSCs were phagocytosed by macrophages in
the spleen and failed to attenuate peritoneal adhesion.
Introduction
Studies demonstrate that mesenchymal stem cells
(MSCs) can repair injuries [1,2] and decrease fibrosis in
the heart [3], lung [4] and kidney [5]. However, the
mechanisms remain controversial. Researchers believe
that the effect is mediated by an increase in mitogenic
[6], anti-inflammatory, anti-apoptotic, immunosuppres-
sive and anti-fibrogenic factors [2,7], as well as differen-
tiation into specific cells [8].
Peritoneal fibrosis and adhesion are the major causes of
ultrafiltration failure in peritoneal dialysis (PD) patients
[9], and postoperative peritoneal adhesions [10] are also
problematic. We previously found that MSCs injected
intravenously attenuated peritoneal adhesion by repairing
mesothelial cells, as well as reducing inflammation and
fibrosis. Rather than the engraftment, the secretion of
multifunctional anti-inflammatory TNFa-stimulating gene
(TSG)-6 by MSCs plays a major role in this effect [11] but
MSCs injected intraperitoneally failed to attenuate perito-
neal adhesion. Studies have shown that MSCs injected
intraperitoneally are activated by the inflammatory micro-
environment of the peritoneal cavity to secrete TSG-6 and
attenuate peritonitis induced by zymosan in mice [12].
Another study found that both intraperitoneal and intrave-
nous injection of MSCs suppress corneal inflammation in
rats by secreting TSG-6 [13]. Our findings were inconsis-
tent with these studies. We do not have direct evidence
that MSCs injected intravenously can secrete TSG-6 and
exert effects on the injured peritoneum.
The aim of this research was to investigate the way in
which MSCs exert their effects on peritoneal adhesion
and to specify the causes for the failure of MSCs injected
intraperitoneally. We demonstrated that intravenously
injected MSCs accumulated in the lung and attenuated
peritoneal adhesion by secreting TSG-6 into the blood,
while intraperitoneally injected MSCs were phagocytosed
by splenic macrophages.
Methods
Acute peritoneal adhesion rat models
This study was approved by the Ethics Committee of The
General Hospital of the People’s Liberation Army (Permit
Number: 2010-X-3-28) with animal care performed
strictly according to established institutional guidelines.
All surgery was performed under pentobarbital anesthe-
sia. Scrape-induced peritoneal adhesions were created in
healthy male Sprague-Dawley (SD) rats weighing 200 g to
250 g. All animals were obtained from the Experimental
Animal Center of the Academy of Military Medical
Sciences (Beijing, China) and housed at constant room
temperature with a 12-hour light/dark cycle. Standard
rodent chow and water were provided ad libitum. The
animals were acclimated for seven days before initiating
the experiment.
Surgical procedures were conducted by a single surgeon
under aseptic conditions in the Laboratory Animal Unit.
Rats were anesthetized with a 2% pentobarbital (30 mg/kg)
intraperitoneal injection. Briefly, a 2-cm vertical midline
incision was made into the abdominal wall and perito-
neum. The dorsal and ventral surfaces of the cecum were
scraped with dry gauze 20 times over an area of 2 × 2 cm2
until petechial bleeding occurred, and the cecum was then
replaced. The parietal peritoneum lateral to the midline
incision was scraped 20 times until petechial bleeding
occurred. The incision was closed in two layers with 4/0
silk sutures [14]. After surgery, the rats were kept in a
single cage and fed a normal diet.
MSCs culture
SD rat bone marrow-derived MSCs/red fluorescent protein
(RFP) was obtained commercially (Cyagen Biosciences,
Sunnyvale, CA, USA). The culture was initiated following
the manufacturer’s instructions. MSCs were placed into 25
cm2 culture flasks and cultured with MSCs growth med-
ium (Cyagen Biosciences, Sunnyvale, CA, USA) at 37°C
under 5% CO2 and 90% humidity. The medium was chan-
ged every three days. Sixth to eighth passage MSCs were
used for the experiments. Following previous methods
[15], fluorescence-activated cell sorting (FACS) analysis
(Beckman Coulter, Indianapolis, IN, USA) was used to
examine the representative markers of MSCs (CD45, CD90
(BD Biosciences, San Diego, California, USA); CD11a,
CD54 (AbD Serotec, Oxford, UK)), and multilineage differ-
entiation of MSCs was examined under adipogenic and
osteogenic differentiation conditions.
Transfection of MSCs with TSG-6 small interfering RNA
(siRNA)
Fifty-percent confluent MSCs were transfected with 20
nM TSG-6-small interfering (si) RNA or the siRNA-
negative control (NC) (GenePharma, Shanghai, China)
using INTERFERin™(Polyplus-transfection SA, Bioparc,
France). At 24 hours after transfection, MSCs were fed
with serum-free medium for 24 hours, prior to experi-
ments. To confirm the knockdown of TSG-6, RNA was
assayed for TSG-6 by RT-PCR (TSG-6 forward primer:
Wang et al. Stem Cell Research & Therapy 2012, 3:51
http://stemcellres.com/content/3/6/51
Page 2 of 10
AGTGATGCGTCCGTCACAGCC, reverse primer: AGA
TGGCTAAACCGTCCAGCTAAGA, product length = 134
bp; GAPDH forward primer: GGCATGGACTGTGGTC
ATGAG, reverse primer: TGCACCACCAACTGCTTAGC,
product length = 87 bp (SBS Genetech, Beijing, China)), and
the protein was assayed for TSG-6 by Western blot (primary
antibodies TSG-6 (1:50) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA)).
Injection of MSCs or recombinant mouse (rm) TSG-6
At 0, 4, 12, 24, or 48 hours after peritoneal scraping, MSCs
(5 × 106) in 1-ml serum-free medium were injected via the
tail vein or peritoneum. At 24 hours after peritoneal scrap-
ing, TSG-6-siRNA-MSCs, TSG-6-siRNA-NC-MSCs or
3 ng/ml rmTSG-6 (97% homology with rat [16]) (R&D
Systems Inc., Minneapolis, MN, USA) in 1-ml serum-free
medium (adapted from our previous experiment [11])
were injected via the tail vein. Rats injected with the
serum-free medium were the negative control, and the
rats without peritoneal scraping were the blank control.
Two-photon fluorescence confocal imaging of MSCs after
injection
A Leica two-photon fluorescence confocal imaging TCS
SP5 system (Leica Microsystems, Mannheim, Germany)
was used to evaluate the distribution of MSCs after injec-
tion. The excitation and emission filter set for green
(autofluorescence) detection was 488 nm and 504 to 569
nm, respectively. The excitation and emission filter set
for red detection was 543 nm and 555 to 624 nm, respec-
tively. MSCs were injected into rats intraperitoneally or
intravenously at 24 hours after scraping. Rats were sacri-
ficed at 4, 12, 24, 48, and 72 hours and 5, 7 days there-
after (n = 3 in each group at each time point). Fresh thick
tissues of the right lung, right lower liver, spleen, and
scraped peritoneum were sampled.
Immunofluorescence staining of lung and spleen
MSCs, TSG-6-siRNA-MSCs, or TSG-6-siRNA-NC-MSCs
were injected into rats intraperitoneally or intravenously at
24 hours after scraping. Rats were sacrificed at 4, 12, 24, 48
and 72 hours and 5, 7 days thereafter (n = 3 in each group
at each time point). The right lung and the spleen were
sampled. Specimens were embedded in optimum cutting
temperature (OCT) compound and stored at -80°C until
use. Frozen tissues were sectioned every 4 μm and placed
on poly-L-lysine precoated slides. The slides were fixed
with 4% paraformaldehyde for 5 minutes at room tempera-
ture, and for 10 minutes at 4°C. The slides were then
blocked with 1% BSA for 30 minutes at room temperature.
The following primary antibodies were incubated overnight
at 4°C: ED-1 (1:50) (Santa Cruz Biotechnology) and TSG-6
(1:50) (Santa Cruz Biotechnology, sc-30140). Secondary
antibodies conjugated with fluorescein isothiocyanate
(FITC) (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were applied for 1 hour at room tem-
perature in a darkened humidified chamber. Finally, the
preparations were mounted in fluorescent mounting med-
ium with 4’,6-diamidino-2-phenylindole (DAPI). Negative
controls did not receive the first antibody. Each tissue sec-
tion was observed under a confocal laser scanning micro-
scope (Olympus FluoView 1000, Tokyo, Japan) at
magnifications of × 600 and × 1800. Three-dimensional
imaging was applied, if necessary.
Enzyme-linked immunosorbent assay (ELISA) of TSG-6 in
rat serum
Rats were sacrificed at 4, 12, 24, 48, or 72 hours, or 5, 7,
14 days after MSCs, TSG-6-siRNA-MSCs, or TSG-6-
siRNA-NC-MSCs injection intravenously at 24 hours after
scraping (n = 3 in each group at each time point). Quanti-
fication of TSG-6 in serum was performed by ELISA
according to the conventional procedure. Absorbance was
measured at 450 nm using a microplate reader (Thermo
Fisher Scientific, Waltham, MA, USA). TSG-6 concentra-
tions were determined with a standard curve constructed
by titrating rmTSG-6. All samples were placed in three
replicate wells. A laboratory-made ELISA kit was prepared
mainly as follows: a 96-well microplate (Corning, Lowell,
MA, USA) was coated with mouse monoclonal antibody
to TSG-6 (Santa Cruz Biotechnology, sc-377277), enzyme-
labeled secondary antibody was purchased from Dako
(Glostrup, Denmark). The correlation coefficiency was
0.995 for the standard curves.
Macroscopic evaluation of peritoneal adhesions
At 0, 4, 12, 24, or 48 hours after peritoneal scraping, MSCs
were injected intraperitoneally. At 24 hours after scraping,
MSCs or rmTSG-6 were injected intravenously. Rats were
sacrificed on day 14 after scraping (n = 6 in each group at
each time point). The size and severity of peritoneal adhe-
sions were evaluated macroscopically by an independent
observer on a scale of 0 to 4 (0, 0%; 1, <25%; 2, 25% to
49%; 3, 50% to 74%; and 4, 75% to 100% adhesions) using
a previously reported scoring system [17].
Histological analysis of peritoneal adhesions
Rats were sacrificed on day 14 after scraping (n = 6 in each
group at each time point). The entire fibrous band was
sampled. Specimens were fixed in 10% formaldehyde for
24 hours. After dehydration, they were embedded in paraf-
fin, and 3-μm thick cross-sections were stained with Mas-
son’s trichrome. Each tissue section was examined by light
microscopy (Olympus IX71, Tokyo, Japan) at magnifications
of × 100 and × 400. Five randomly selected fields in each
section were evaluated by an independent pathologist (at a
magnification of × 100). The extent of fibrosis was scored as
0 (negative), 1 (weak), 2 (medium), or 3 (intensive).
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Statistical analysis
Analysis was done using SPSS Statistics, version 17.0.2.
Results are presented as mean values ± standard devia-
tions. Multiple comparisons of parametric data were per-
formed using one-way analysis of variance (ANOVA).
Nonparametric data were compared with the Mann-
Whitney U-test to identify differences between groups. A
value of P <0.05 was considered to indicate statistical
significance.
Results and discussion
MSCs injected intraperitoneally failed to attenuate
peritoneal adhesion
We previously found that MSCs injected intraperitone-
ally 24 hours after scraping failed to attenuate peritoneal
adhesion [11]. One related study reported that MSCs
injected intraperitoneally into mice 15 minutes after
zymosan administration attenuated peritonitis [12].
Another study reported that both intraperitoneal and
intravenous injection of MSCs into rats immediately fol-
lowing injury can suppress corneal inflammation [13].
Our findings were inconsistent with these reports, which
injected MSCs as early as possible. We previously found
that infiltration of neutrophils (the active inflammation
phase) peaked 12 to 24 hours after scraping [11], so we
selected an earlier and wider range of time points for
injection. At 0, 4, 12, 24, or 48 hours after scraping,
MSCs (identifications are shown in Additional file 1,
Figure S1) were injected intraperitoneally. On day 14
after scraping, the medium-injected rats demonstrated
dense adhesions with high adhesion scores. The rats that
had MSCs injected intraperitoneally showed no apparent
reduction in adhesions. We observed no significant dif-
ference among the groups (Figure 1) (P >0.05, n = 6,
respectively). Therefore, we concluded that MSCs
injected intraperitoneally did not attenuate peritoneal
adhesion, regardless of the time of injection.
It has become apparent that MSCs repair injured tissues
without engraftment [18]. In fact, MSCs secrete a num-
ber of cytokines and growth factors that alter the tissue
microenvironment. In order to evaluate why MSCs
injected intraperitoneally failed to function efficiently, we
next investigated the differences in the distribution of
intraperitoneally and intravenously injected MSCs.
MSCs injected intraperitoneally were phagocytosed by
macrophages
Two-photon microscopy has advantages over traditional
confocal fluorescence microscopy, including decreased
out of focus photodamage and increased intrinsic optical
sectioning and imaging depths [19]. To track the distri-
bution of MSCs after injection intravenously or intraperi-
toneally, we used two-photon fluorescence confocal
imaging to observe the fresh thick tissues of lung, spleen,
liver and peritoneum. The findings showed that MSCs
injected intravenously accumulated mainly in the intersti-
tial areas of the lung appearing as ‘emboli’ 4 hours after
injection, then decreased gradually and began to accumu-
late in the spleen and liver, but the RFP signal persisted in
the lung for 7 days (Figure 2A1); no signal was found in
the injured peritoneum throughout the entire period (data
not shown). Immunofluorescence microscopy for RFP and
Figure 1 Effects of intraperitoneally injected mesenchymal stem cells (MSCs) on the severity of acute peritoneal adhesions. MSCs
injected intraperitoneally into rats either immediately or 4, 12, 24, or 48 hours after peritoneal scraping yielded no apparent reduction in
adhesions (n = 6).
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ED-1 double-stained cells showed that few MSCs were
phagocytosed by macrophages in the interstitial areas
between alveoli of the lung (Figure 2A2). While MSCs
injected intraperitoneally accumulated mainly in the
spleen appearing as ‘debris’ 4 hours after injection, the
signal increased and peaked at 24 hours after injection
(Figure 2B1). The changes of signal in the liver were simi-
lar. No signal was found in the lung or the injured perito-
neum (data not shown). Immunofluorescence microscopy
showed apparent phagocytosis of MSCs by macrophages
even at 4 hours after injection (Figure 2B2, Additional file
2, Video S1 and Additional file 3, Video S2).
Our findings were similar to our previous results when
we used an in vivo imaging system to track the distribu-
tion of MSCs [11]. The vast majority of MSCs injected
intravenously accumulated in the lungs [18,20]. This dis-
tribution may be due to the size of MSCs (20 μm to
30 μm) relative to pulmonary capillaries (14 μm in dia-
meter), which may prevent MSCs from passing through
the pulmonary circulation. Researchers found that MSCs
injected intravenously into rat stroke models were transi-
ently trapped in the lungs, then were sequestered in the
spleen [21]; Minjie Lu et al. injected MSCs into the left
anterior descending artery of a mini-pig with acute
Figure 2 The distributions of mesenchymal stem cells (MSCs) injected into rats intravenously or intraperitoneally. A. The distribution of
MSCs injected intravenously. A1. The accumulation of MSCs in the lung tracked by two-photon fluorescence confocal imaging. Red symbolizes red
fluorescent protein (RFP); Green symbolizes autofluorescence of the lung. Magnification: × 200, × 600. A2. MSCs did not co-localize with macrophages
in the lung, as observed by immunofluorescence microscopy. Red symbolizes RFP; Green symbolizes ED-1 of macrophages. Magnification: × 600,
× 1800. B. The distribution of MSCs injected intraperitoneally. B1. The accumulation of MSCs in the spleen tracked by two-photon fluorescence
confocal imaging. Red symbolizes RFP; Green symbolizes autofluorescence of the spleen. Magnification: × 200, × 600. B2. The majority of MSCs
co-localized with macrophages in the spleen, as observed by immunofluorescence microscopy. Red symbolizes RFP; Green symbolizes ED-1 of
macrophages. Magnification: × 600, × 1800.
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myocardial infarction, and found that the spleen was the
main extracardial organ to trap MSCs [22]. One study
reported that MSCs were observed in the spleen after
intraperitoneal injection [23], but no study has deter-
mined whether the trapped MSCs were intact.
ED-1 is a transmembrane protein restricted mainly to
monocyte-macrophages. In macrophages, ED-1 is loca-
lized mainly in lysosomes and endosomes [24]. We found
that MSCs accumulated in the lung were generally of a
normal size, and RFP could not co-localize with ED-1. We
speculated that these MSCs were intact. While the MSCs
accumulated in the spleen were generally fragmented, and
most of the RFP could partly or wholly co-localize with
ED-1. We speculated that these MSCs were damaged by
local macrophages. It was interesting that macrophages in
the lung did not alter the survival of MSCs. Several possi-
ble reasons may explain this phenomenon. First, MSCs
accumulated in the interstitial areas of the lung. Unlike
alveolar macrophages which have an active response with
enough phagocytes to engulf particles [25], interstitial
macrophages are transitional stages between blood macro-
phages and alveolar macrophages. Interstitial macrophages
have a role in limiting inflammation and antigen presenta-
tion [25,26]. While MSCs have low immunogenicity and
may escape detection by the host immune system upon
transplantation, MSCs may also inhibit the activation of
macrophages [1,27]. Second, monocyte-derivied macro-
phages have no proliferative potential in tissues. The
macrophage population is maintained by the influx of
monocytes from peripheral blood into tissues; the influx
rate of monocytes is high in the spleen but low in the
lungs [28]. Thus, the function of macrophages in the lung
may be relatively stable as they are exposed to fewer influ-
ences from peripheral blood. Instead of being phagocy-
tosed by macrophages, MSCs accumulated in the lung
might further translocate to the extrapulmonary regional
lymph nodes after entering lymphatic capillaries [25].
However, the means by which MSCs injected into the
peritoneal cavity accumulated in the spleen shortly after
injection remain unclear, as does why our results differed
from those of previous studies. Further investigations
must be performed to answer these questions.
MSCs accumulated in the lung after intravenous injection
could express TSG-6
We previously examined the cytokine profile in serum-
starved MSCs-conditioned medium and found that TSG-6
was released most abundantly. Matrix metalloproteinase
(MMP)-8, Fas ligand, vascular endothelial growth factor
(VEGF), inter-cellular adhesion molecule (ICAM)-1, some
inflammatory and chemotactic factors, were also released
by MSCs [11]. TSG-6 has multifunctional anti-inflamma-
tory effects. Transgenic inactivation of the gene increased
inflammation, and over-expression of the gene decreased
inflammation [12]. We found that TSG-6 secreted by
MSCs inhibited inflammation and promoted the repair of
mesothelial cells, subsequently reducing peritoneal adhe-
sion [11]. However, we had no direct evidence that MSCs
could affect injured peritoneum from a distance. Some
studies have reported that cells trapped in the lungs
secrete soluble factors into the blood to enhance the repair
of other tissues [18].
Immunofluorescence microscopy showed that MSCs
accumulated in the lung after intravenous injection
expressed TSG-6 within 12 hours (Figure 3A1), while
MSCs accumulated in the spleen did not express TSG-6
(Figure 3A2). ELISA showed that the concentration of
TSG-6 in serum was increased at 4 hours after intravenous
injection of MSCs, compared with that in the medium-
injected group (Figure 3B) (P <0.05, n = 3, respectively).
The concentration of TSG-6 in serum increased gradually
within 7 days after MSCs injection, while the MSCs injec-
tion weakened this trend, except for 4 hours after injection
(Figure 3B). The changes of serum TSG-6 in the group
injected with MSCs intraperitoneally were similar to those
in the medium-injected group (Figure 3B).
We previously found that acute inflammation of
injured peritoneum peaked at 12 to 24 hours after scrap-
ing and the optimal benefit was attained when MSCs
were injected at 24 hours after scraping [11]. Therefore,
the anti-inflammatory effects of TSG-6 secreted by
inflammation-stimulated MSCs were important for their
benefits. MSCs accumulated in the lung transiently
secreted TSG-6 into the blood, resulting in inhibition of
the excessive inflammation of injured peritoneum, which
in turn stimulated more weakly the secretion of TSG-6
by MSCs. While the secretion of TSG-6 in the control
group increased 48 hours after peritoneal scraping, it
might not inhibit the active inflammation efficiently and,
thus, failed to reduce peritoneal adhesions.
We found that intraperitoneally injected MSCs were
damaged by macrophages in the spleen and did not
express or secrete TSG-6 into the blood. So TSG-6
secreted by live MSCs may be a key player that attenu-
ates peritoneal adhesion. These findings may explain the
questions we stated at the beginning of this paper.
MSCs injected intravenously attenuated peritoneal
adhesion by secreting TSG-6
To further evaluate the role of TSG-6 secreted by MSCs
in the attenuation of peritoneal adhesion, we knocked
down the expression of TSG-6 in MSCs by transient
transfection with a TSG-6-siRNA [see Additional file 4,
Figure S2]. No TSG-6 expression by TSG-6-siRNA-
MSCs in the lung at 4 hours after injection was observed
by immunofluorescence microscopy (Figure 4A). ELISA
showed no increment of TSG-6 in serum at 4 hours after
injection of TSG-6-siRNA-MSCs (Figure 4B). Compared
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Figure 3 The expression of TNFa-stimulating gene (TSG)-6 in mesenchymal stem cells (MSCs) injected into rats intravenously. A. The
expressions of TSG-6 in MSCs accumulated in the lung and the spleen. A1. The majority of MSCs accumulated in the lung expressed TSG-6
within 12 hours, as observed by immunofluorescence microscopy. Red symbolizes red fluorescent protein (RFP); Green symbolizes TSG-6.
Magnification: × 600, × 1800. A2. The majority of MSCs accumulated in the spleen did not express TSG-6, as observed by immunofluorescence
microscopy. Red symbolizes RFP; Green symbolizes TSG-6. Magnification: × 600, × 1800. B. The serum TSG-6 concentration was evaluated by
enzyme-linked immunosorbent assay (ELISA). Serum TSG-6 level was increased at 4 hours after intravenous injection of MSCs, compared with the
medium-injected group. There was no difference between the group injected with MSCs intraperitoneally and the medium-injected group.
Three independent samples were placed in three replicate wells. * compared with the medium-injected group, P <0.05; # compared with the
normal group, P <0.05. TNFa, tumor necrosis factor a.
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with the medium-injected group, TSG-6-siRNA-MSCs
had no significant effect on the size, severity (Figure 4C1)
or collagen deposition (Figure 4C2, 4C3) of peritoneal
adhesions 14 days after scraping. However, both the size,
severity and the collagen depositions of peritoneal adhe-
sions were reduced in rats injected with rmTSG-6 in a
manner similar to that in the MSCs-injected group
(Figure 4C1, C2, 4C3). Our data demonstrate that TSG-6
Figure 4 TNF-stimulating gene (TSG)-6 secreted by mesenchymal stem cells (MSCs) attenuated peritoneal adhesion. A. No TSG-6
expression by TSG-6- small interfering (si) RNA-MSCs in the lung at 4 hours after injection was observed on immunofluorescence microscopy.
Red symbolizes red fluorescent protein (RFP); Green symbolizes TSG-6. Magnification: × 600, × 1800. B. Serum TSG-6 concentrations as evaluated
by enzyme-linked immunosorbent assay (ELISA). No obvious increment of TSG-6 after TSG-6-siRNA-MSCs injection was detected compared with
the medium-injected group. The concentration of TSG-6 in the TSG-6-siRNA-MSCs-injected group at 4 hours after injection was lower than that
in the MSCs-injected group. Three independent samples were placed in three replicate wells. * compared with the medium-injected group, P
<0.05; # compared with the normal group, P <0.05; & compared with the MSCs-injected group, P <0.05. C. The effects of TSG-6 on acute
peritoneal adhesions. C1. The TSG-6-siRNA-MSCs-injected group exhibited no significant reduction in adhesion scores on day 14 after scraping
but the recombinant mouse (rm) TSG-6-injected group exhibited an obvious reduction in peritoneal adhesion scores similar to the MSCs-injected
group. * compared with the medium-injected group, P <0.05 (n = 6). C2. Histological changes were evaluated using Masson’s trichrome staining.
The TSG-6-siRNA-MSCs-injected group revealed no reduction in fibrosis in the scraped peritoneum 14 days after scraping. But the rmTSG-6-
injected group revealed a distinct reduction in peritoneal fibrosis similar to the MSCs-injected group. Magnification: × 100, × 400. C3. The
peritoneal fibrosis scores were not reduced by injecting TSG-6-siRNA-MSCs but by injecting rmTSG-6 or MSCs. * compared with the medium-
injected group, P <0.05 (n = 6).
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secretion by MSCs is necessary for attenuation of perito-
neal adhesions.
TSG-6 is a hyaluronan (HA)-binding glycoprotein with
multifunctional anti-inflammatory effects. MSCs can block
the recruitment of neutrophils by secreting TSG-6 [12] via
a CD44/HA/TSG-6 mediated blocking mechanism [29].
Research found that neutrophils of thioglycollate-induced
peritonitis were higher in TSG-6-deficient animals than in
wild-type animals, but were dramatically suppressed by
intravenous injection of rmTSG-6 [30]. MSCs may be acti-
vated by an inflammatory microenvironment to secrete
TSG-6. In addition, TSG-6/HA/CD44 activates the mito-
gen-activated protein kinase (MAPK) pathway [31] and
enhances the migration and proliferation of injured cells
[32]. TSG-6-mediated formation of heavy chain-HA com-
plexes is also involved in remodeling extracellular matrix
and regulating cell migration and proliferation [31,33]. We
suggest that TSG-6 secreted by MSCs could protect the
injured peritoneum from excessive inflammatory response
and promote the repair of mesothelial cells, thus reducing
the formation of fibrosis [11].
Conclusions
Our findings suggest that intravenously injected MSCs
may accumulate in the lung and attenuate peritoneal
adhesion by secreting TSG-6, while intraperitoneally
injected MSCs fail to attenuate peritoneal adhesion
probably due to phagocytosis by splenic macrophages.
Additional material
Additional file 1: Figure S1. Identifications of Sprague-Dawley (SD)
rat bone marrow-derived mesenchymal stem cells (MSCs). A.
Representative markers of MSCs. Fluorescence-activated cell sorting
(FACS) analysis showed that the positive proportion of cells displaying
CD90 was 97.0%, CD54 was 88.8%, CD11a was 10.7% and CD45 was
8.4%. B. Multilineage differentiation of MSCs. B1. Under osteogenic
differentiation conditions, cells displayed extracellular calcium phosphate
precipitates as identified by alizarin red staining. Magnification: × 100. B2.
Under adipogenic differentiation conditions, cells accumulated
intracellular lipid droplets as revealed by Oil red staining. Magnification: ×
400.
Additional file 2: Video S1. Phagocytosis of mesenchymal stem cells
(MSCs) 12 hours after intraperitoneal injection by macrophages in
the spleen. MSCs partly co-localized with macrophages in the spleen, as
observed by a dynamic three-dimensional image of immunofluorescence
microscopy. Red symbolizes RFP; Green symbolizes ED-1 of macrophages.
Magnifications: × 1800.
Additional file 3: Video S2. Phagocytosis of mesenchymal stem cells
(MSCs) 48 hours after intraperitoneal injection by macrophages in
the spleen. MSCs wholly co-localized with macrophages in the spleen
48 hours after intraperitoneal injection, as observed by a dynamic three-
dimensional image of immunofluorescence microscopy. Red symbolizes
RFP; Green symbolizes ED-1 of macrophages. Magnifications: × 1800.
Additional file 4: Figure S2. Knockdown efficiency of TNFa-
stimulating gene (TSG)-6 in mesenchymal stem cells (MSCs). A.
Knockdown efficiency of mRNA in MSCs was approximately 82.9%, as
evaluated by reverse-transcriptase polymerase chain reaction (RT-PCR),
TSG-6 product length = 134 bp, GAPDH product length = 87 bp. *
compared with normal MSCs, P <0.05; # compared with 24-hour serum-
starved MSCs, P <0.05. B. Knockdown efficiency of protein in MSCs was
approximately 43.5%, as evaluated by Western blot. * compared with
normal MSCs, P <0.05; # compared with 24-hour serum-starved, P <0.05.
Abbreviations
ANOVA: one-way analysis of variance; bp: base pair; BSA: bovine serum
albumin; ELISA: enzyme-linked immunosorbent assay; FACS: fluorescence-
activated cell sorting; HA: hyaluronan acid; ICAM: inter-cellular adhesion
molecule; MMP: matrix metalloproteinase; MAPK: mitogen-activated protein
kinase; MSCs: mesenchymal stem cells; PD: peritoneal dialysis; RFP: red
fluorescent protein; rm: recombinant mouse; RT-PCR: reverse transcriptase-
polymerase chain reaction; SD: Sprague-Dawley; siRNA: small interfering RNA;
TSG-6: TNFα-stimulating gene-6; VEGF: vascular endothelial growth factor.
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